Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.

chronic hepatitis C direct-acting antivirals hepatocellular carcinoma pegylated interferon risk factor

Journal

Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801

Informations de publication

Date de publication:
May 2019
Historique:
received: 21 02 2018
revised: 09 11 2018
accepted: 26 12 2018
pubmed: 10 1 2019
medline: 10 1 2019
entrez: 10 1 2019
Statut: ppublish

Résumé

In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 ± 26.2 months. The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years. The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods.

Identifiants

pubmed: 30623521
doi: 10.1111/hepr.13310
doi:

Types de publication

Journal Article

Langues

eng

Pagination

570-578

Subventions

Organisme : a Grant-in Aid for Scientific Research from the Japan Agency for Medical Research and Development
Organisme : a Grant-in Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology

Informations de copyright

© 2019 The Japan Society of Hepatology.

Auteurs

Ryoko Yamada (R)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Naoki Hiramatsu (N)

Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai.

Tsugiko Oze (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Ayako Urabe (A)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Yuki Tahata (Y)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Naoki Morishita (N)

Department of Gastroenterology and Hepatology, Minoh City Hospital, Minoh.

Takahiro Kodama (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Hayato Hikita (H)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Ryotaro Sakamori (R)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Takayuki Yakushijin (T)

Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka.

Akira Yamada (A)

Department of Gastroenterology and Hepatology, Sumitomo Hospital, Osaka.

Hideki Hagiwara (H)

Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki.

Eiji Mita (E)

Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka.

Masahide Oshita (M)

Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka.

Toshifumi Itoh (T)

Department of Gastroenterology and Hepatology, Japan Community Health care Organization Osaka Hospital, Osaka.

Hiroyuki Fukui (H)

Department of Gastroenterology and Hepatology, Yao Municipal Hospital, Yao.

Yoshiaki Inui (Y)

Department of Gastroenterology and Hepatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya.

Taizo Hijioka (T)

Department of Gastroenterology and Hepatology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano.

Masami Inada (M)

Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka.

Kazuhiro Katayama (K)

Department of Gastroenterology and Hepatology, Osaka International Cancer Institute, Osaka.

Shinji Tamura (S)

Department of Gastroenterology and Hepatology, Minoh City Hospital, Minoh.

Atsuo Inoue (A)

Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka.

Yasuharu Imai (Y)

Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda.

Tomohide Tatsumi (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Toshimitsu Hamasaki (T)

Department of Gastroenterology and Hepatology, Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan.

Norio Hayashi (N)

Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki.

Tetsuo Takehara (T)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita.

Classifications MeSH